Discontinuation of quetiapine from an NIMH-funded trial due to serious adverse events.
Jeste
Dilip V
DV
Jin
Hua
H
Golshan
Shahrokh
S
Mudaliar
Sunder
S
Glorioso
Danielle
D
Fellows
Ian
I
Kraemer
Helena
H
Arndt
Stephan
S
D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003865:Major Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D003987:Dibenzothiazepines / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D009315:National Institute of Mental Health (U.S.) / Q000706:statistics & numerical data; D000069348:Quetiapine Fumarate; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data*; D012044:Regression Analysis; D012109:Research Support as Topic / Q000706:statistics & numerical data; D014481:United States
D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D000069348:Quetiapine Fumarate